ryo

Stroke is the leading cause of the need for long-term care in Japan, affecting over 100,000 people annually. It is divided into two major types: Cerebral Infarction (ischemic stroke, 70–80%), where a blood vessel in the brain is blocked, and Intracerebral Hemorrhage or Subarachnoid Hemorrhage (20–30%), where a blood vessel ruptures. The response immediately after onset for either type significantly influences the rest of the patient's life.

Subarachnoid Hemorrhage (SAH), classified as a type of "stroke," is covered by medical and life insurance policies. It is particularly advantageous if the policy includes a rider for Critical Illnesses (Cancer, Acute Myocardial Infarction, and Stroke). The benefit amount varies based on the contract details (daily hospitalization benefit, surgical payout, and riders). The average hospital stay is 2–4 months (approx. 60–120 days). You can reduce the financial burden by combining the payout with the public health insurance's High-Cost Medical Care Benefits (monthly cap ≈¥80,000). Below are typical benefit examples and precautions. For actual amounts, consult your policy or insurance company.

Subarachnoid Hemorrhage (SAH) requires advanced, time-sensitive treatments like Coil Embolization and Clipping Surgery, leading to total medical costs potentially reaching several million yen. This financial aspect can be a significant source of anxiety for patients and their families.

Subarachnoid Hemorrhage (SAH) requires emergency surgery, but the subsequent length of hospitalization varies greatly depending on the treatment method and severity. Notably, as of 2025, the shift to Coil Embolization (which is less invasive) as the dominant treatment has led to a general trend of shorter hospital stays compared to the past.

Treatment for Subarachnoid Hemorrhage (SAH) does not end with curative surgery for the aneurysm. Subsequent rehabilitation determines the patient's social reintegration and Quality of Life (QOL). Unlike Intracerebral Hemorrhage, rehabilitation after SAH places critical importance on managing higher brain dysfunctions, such as memory impairment and chronic fatigability.

There was a time when surviving Subarachnoid Hemorrhage (SAH) was considered "lucky." However, as of 2025, with appropriate treatment and rehabilitation, it has become a disease where approximately 60% of patients can return to a nearly normal life. Yet, the reality is that many survivors still suffer from less visible residual deficits, such as memory impairment and chronic fatigue.

Subarachnoid Hemorrhage (SAH) is an extremely dangerous disease with a high fatality rate upon onset. Fortunately, many actions have been scientifically proven to be effective in prevention. Specifically, "Smoking Cessation" and "Strict Blood Pressure Management" are the most powerful strategies to reduce the risk of SAH by more than half.

The treatment of Subarachnoid Hemorrhage (SAH) hinges on completely sealing the ruptured aneurysm within 72 hours of onset. The swiftness of this initial treatment is the single most important factor determining the patient's survival and prognosis, as it prevents the most dangerous complication: re-bleeding.

Subarachnoid Hemorrhage (SAH) is an extremely dangerous condition where the subsequent prognosis is often determined within just the first few minutes after onset. The symptoms are dramatic, with the "worst headache ever experienced" appearing in nearly 100% of patients.

Subarachnoid Hemorrhage (SAH) is often treated as a uniform condition, but its prognosis and treatment strategy differ greatly depending on the cause of the bleeding. While ruptured unruptured aneurysms, often detected during brain checkups, account for over 80% of cases, Non-Aneurysmal Subarachnoid Hemorrhage (NA-SA), where no aneurysm is found, generally has a relatively favorable prognosis.SAH is primarily classified by its cause, rather than the location or shape of the bleeding. This classification is the standard used in the guidelines of the Japan Neurosurgical Society.